Results 1 to 10 of about 21,293 (203)

An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate [PDF]

open access: yesDrugs in R&D
Background and Objectives The nucleoside reverse transcriptase inhibitors tenofovir alafenamide fumarate and tenofovir disoproxil fumarate are frequently employed in treating human immunodeficiency virus.
Derek E. Murrell   +8 more
doaj   +2 more sources

Comparative risk of osteoporosis and fractures in chronic hepatitis B patients: Tenofovir disoproxil fumarate vs. entecavir in a Korean nationwide cohort [PDF]

open access: yesJHEP Reports
Background & Aims: The optimal antiviral agent for patients with chronic hepatitis B (CHB) at risk for osteoporosis remains debated. The aim of this study was to compare the incidence of osteoporosis and osteoporotic fractures between patients ...
Yoon E. Shin   +5 more
doaj   +2 more sources

MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments [PDF]

open access: yes, 2013
Background: Oral and vaginal preparations of tenofovir as pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection have demonstrated variable efficacy in men and women prompting assessment of variation in drug concentration as an ...
A Pruvost   +39 more
core   +21 more sources

Tenofovir-induced osteopenia and hyperparathyroidism: A case report and literature review

open access: yesFrontiers in Endocrinology, 2023
Tenofovir disoproxil fumarate is the first-line antiviral therapy for chronic viral hepatitis B, but long-term use is associated with renal failure and hypophosphatemic osteomalacia.
Jing Zeng   +4 more
doaj   +1 more source

Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B

open access: yesThe Turkish Journal of Gastroenterology, 2022
Background: We aimed to investigate the long-term effects of tenofovir disoproxil fumarate and entecavir treatment on bone mineral density and evaluated the fracture risk assessment tool score in patients with chronic hepatitis B.
Resul Kahraman   +7 more
doaj   +1 more source

Osteopenia in a young man associated with the use of tenofovir disoproxil fumarate

open access: yesClinical Case Reports, 2022
Tenofovir disoproxil fumarate is a recommended first‐line therapy for patients with chronic hepatitis B, although the frequent Tenofovir disoproxil fumarate related adverse drug reactions are nephrotoxicity and bone toxicity.
Chunmei Li, Hui Li, Ming Gong, Jia Wei
doaj   +1 more source

A new stability indicating RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulation

open access: yesFuture Journal of Pharmaceutical Sciences, 2021
Background To establish a simple, sensitive, accurate, precise, efficient, economical RP-UPLC method for simultaneous estimation of Doravirine, Lamivudine and Tenofovir disoproxil fumarate in bulk and their combined pharmaceutical formulations ...
Swetha Addanki, B. Ramya Kuber
doaj   +1 more source

Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis

open access: yesBeni-Suef University Journal of Basic and Applied Sciences, 2022
Background A meta-analysis was made to assess the impact of entecavir comparison with tenofovir disoproxil fumarate as nucleos(t)ide analogue on hepatic cellular carcinoma (HCC). The study had subjects with chronic hepatitis B virus (HBV).
Sara M. Tony   +3 more
doaj   +1 more source

Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial

open access: yesEClinicalMedicine, 2021
Background: Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp). Several cohorts reported that people treated by tenofovir disoproxil fumarate and emtricitabine are less likely to develop SARS ...
Jean-Jacques Parienti   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy